Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KRYSTAL-4: adagrasib plus pembrolizumab and chemotherapy versus placebo plus pembrolizumab and chemotherapy in untreated KRAS G12C-mutated advanced nonsquamous NSCLC
CTR20251671Phase 3Active
- Sponsor
- Mirati Therapeutics, Inc., a Bristol-Myers Squibb Company/ 百时美施贵宝（中国）投资有限公司/ Patheon Inc./ Patheon Inc.; Bristol-Myers Squibb Company
- Start
- Jul 2025
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of adagrasib in non-small cell lung cancer (NSCLC), sponsored by Mirati Therapeutics, Inc., a Bristol-Myers Squibb Company/ 百时美施贵宝（中国）投资有限公司/ Patheon Inc./ Patheon Inc.; Bristol-Myers Squibb Company. Started Jul 2025; status: active.
02
Drugs
adagrasib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20251671.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251671.